Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Globe Newswire•12/11/2026•16:05 ET
0
Key Highlights
- ➤$174.2 million cash, equivalents, and marketable securities fund operations into first-half 2029
- ➤$155.5 million gross proceeds raised through upsized IPO and Sanofi private placement
- ➤STX-1150 Phase 1 enrollment continues; initial clinical data expected in first-half 2027
- ➤Sanofi collaboration expanded to include Scribe’s ELXR epigenetic silencing technology
- ➤STX-1150 delivered over 50% LDL-C reductions sustained two years in non-human primates
Expert Statements
Benjamin Oakes, Co-founder and Chief Executive Officer of Scribe Therapeutics
“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients”
Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400
Continued enrollment in first-in-human Phase 1 clinical trial of STX-1150, the Company’s epigenetic silencing therapy for LDL-C lowering, with initial clinical data expected in the first half of 2027
Get started
Create a free account to read the full story.